STEMVAC

N/A

Report date: 2026/03/10 20:00:16

Base Information

Drug NameSTEMVAC
Drug Alias NameEP-101
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccine
Mechanisms of ActionTh1 cells stimulants
TargetsCadherin 3p53-binding protein Mdm-2Endoglin +[4] 
Therapy Area/IndicationsHR-positive breast cancerCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEpithany
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Washington
Inactive CompaniesN/A
Active IndicationsHR-positive breast cancerCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A